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ABSTRACT
Objectives: To evaluate the short-term symptomatic efficacy of rofecoxib and diclofenac
versus placebo in acute episodes of shoulder pain.
Design: Randomized controlled trial of 7 days.
Setting: Rheumatologists and/or general practitioners totaling 47.
Participants: Acute shoulder pain.
Interventions: Rofecoxib 50 mg once daily, diclofenac 50 mg three times daily, and placebo.
Outcome measures: Pain, functional impairment, patient’s global assessment of his/her
disease activity, and local steroid injection requirement for persistent pain. The primary variable
was the Kaplan-Meier estimates of the percentage of patients at day 7 fulfilling the definition of
success (improvement in pain intensity and a low pain level sustained to the end of the 7 days
of the study; log-rank test).
Results: There was no difference in the baseline characteristics between the three groups
(rofecoxib n¼88, placebo n¼94, and diclofenac n¼89). At day 7, the Kaplan-Meier estimates
of successful patients was higher in the treatment groups than in the placebo (54%, 56%, and
38% in the diclofenac, rofecoxib, and placebo groups respectively, p ¼ 0.0070 and p ¼ 0.0239
for placebo versus rofecoxib and diclofenac, respectively). During the 7 days of the study, there
was a statistically significant difference between placebo and both active arms (rofecoxib and
diclofenac) in all the evaluated outcome measures A local steroid injection had to be performed
in 33 (35%) and 19 (22%) patients in the placebo and rofecoxib group respectively. Number
needed to treat to avoid such rescue therapy was 7 patients (95% confidence interval 5–15).
Conclusion: This study highlights the methodological aspects of clinical trials, e.g., eligibility
criteria and outcome measures, in acute painful conditions. The data also establish that
diclofenac and rofecoxib are effective therapies for the management of acute painful shoulder
and that they reduce the requirement for local steroid injection.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
Shoulder pain is the third most common musculoskeletal
symptom encountered in medical practice after back and
neck pain [1,2]. A wide range of potential pathoanatomic
entities can give rise to shoulder pain, from simple sprains to
massive rotator tears [3]. Most of these different conditions
can be adequately diagnosed after careful interview and
physical examination of the patient [4]. Options for the
medical management of acute shoulder pain include systemic
(e.g., nonsteroidal anti-inﬂammatory drugs [NSAIDs]) and
local (e.g., injection of steroids) approaches. Several studies
have investigated the efﬁcacy of injectable steroids and/or the
combination of injectable steroids and NSAIDs [5–12].
Given the invasiveness of injections, many practitioners
prefer an initial trial of oral NSAIDs with injections reserved
for patients with persistent pain or severe pain at the time of
initial presentation [3]. Despite this pragmatic approach, such
a procedure was until recently [13] little evaluated. Among
the different conventional NSAIDs, diclofenac is one of the
most frequently used for such conditions in daily practice
[14]. Because of a better gastrointestinal safety proﬁle, coxibs
might be preferred in particular in patients at risk of
gastrointestinal complications [15]. Efﬁcacy of rofecoxib 50
mg once daily has been demonstrated in different acute pain
human models (e.g., post–dental surgery [16], primary
dysmenorrhea [17], and post–orthopedic surgery pain [18]).
These ﬁndings prompted us to conduct a seven-day clinical
trial evaluating the short-term symptomatic efﬁcacy of
rofecoxib in acute, painful episodes of rotator-cuff syndrome
using both potentially negative (placebo) and active (diclofe-
nac) control groups. A secondary but clinically relevant end
point was the requirement for local steroid injections.
Although one of the study drugs (rofecoxib) was withdrawn
from the market in October 2004, the data are being reported
now for the sake of completeness and transparency.
METHODS
Participants
The inclusion criteria were selected to optimize the proba-
bility of recruiting patients suffering from an acute painful
episode of tendonitis of the rotator cuff. For this purpose, the
following criteria were chosen: patients less than 60 years of
age, suffering from an acute (less than 7 d), painful (numerical
rating scale [NRS] 0–10   5 in which 0 and 10 are the best and
worst conditions, respectively), episode occurring in the
shoulder area with the following ﬁndings at physical exami-
nation: no limitation of the glenohumeral external rotation
and a painful Job test [19,20]. A schema explaining the Job test
was provided to all the 47 investigators. Moreover, in order to
enter the trial, the patients had to have no contraindication
for receiving either diclofenac or rofecoxib (e.g., history of
NSAID allergy; renal, liver, or cardiac failure; or pregnancy).
Any NSAID intake other than the study drug was
prohibited during the study. In case of previous intake, the
NSAIDs had to be discontinued at least 3 d before enroll-
ment. During the baseline visit, the following information was
also collected: lateralization (right- or left-handedness) and
history of progression of the symptoms with the a priori
deﬁned following four categories: (i) no history of chronic
pain before this episode; (ii) history of chronic pain before
this ﬁrst acute episode; (iii) history of similar acute episodes
without any history of chronic pain between episodes; and (iv)
history of similar acute episodes with history of chronic pain
between episodes. Therefore, the date of onset of shoulder
disease was not always that of the current episode.
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Editorial Commentary
Background: Shoulder pain is a very common complaint that presents in
primary care, and there are many different possible causes. Acute pain
would normally be managed with nonsteroidal anti-inflammatory drugs
(NSAIDs), supplemented with steroid injections (which are often reserved
for the treatment of severe or persistent pain). One NSAID, diclofenac, is
used frequently for this condition, but other NSAIDs might also be
effective. A subgroup of NSAIDs called the Cox-2 selective inhibitors
specifically inhibit one particular enzyme (cyclo-oxygenase, shortened to
Cox-2) which is involved in inflammation and pain. These drugs are
thought to be less likely to cause stomach irritation than other NSAIDs.
Therefore the researchers in this study carried out a short-term, three-
way clinical trial comparing diclofenac with one particular Cox-2
inhibitor, rofecoxib, and placebo in patients with acute shoulder pain.
However, rofecoxib was withdrawn from the market in September 2004
because of evidence that use of the drug was associated with an
increased risk of heart attacks and strokes, and controversy remains
regarding the risk of such events among users of other Cox-2 inhibitors.
What this trial shows: The main aim of this trial was to compare the
level of pain relief over seven days of treatment with either diclofenac or
rofecoxib, as compared to placebo. The primary outcome measure used
in the trial was the proportion of patients achieving a 50% or greater
decrease in pain levels over the course of the study, measured using a
numerical rating scale. A total of 273 participants were recruited into the
trial and at day 7 the proportion achieving a 30% decrease in pain was
38% in the placebo arm, 54% in the diclofenac arm, and 56% in the
rofecoxib arm. The differences in this outcome measure between
diclofenac and placebo and between rofecoxib and placebo were
statistically significant; however, the researchers did not carry out a
direct comparison between diclofenac and rofecoxib. The rates of
adverse events were roughly comparable between all three arms of the
trial, although the study was not originally planned to be large enough
to detect differences in the rates of such events, so it is not possible to
conclude whether there was any true difference.
Strengths and limitations: The randomization procedures used in the
study minimize the possibility of bias in assigning patients to treatment
arms. Bias in assessment of outcomes was also minimized by ensuring
that steps were taken to prevent investigators and patients from
knowing which drugs a particular patient received until the end of the
trial. A key limitation of the study is the short follow-up, only seven days,
and it is therefore unclear whether efficacy and safety of these drugs
would continue for the much longer periods of time (weeks or even
months) for which these patients might need pain relief. Finally, patients
randomized to the placebo arm received no treatment for the seven days
of the study other than acetaminophen or steroid injections (which
would result in withdrawal from the trial). This design does not limit
interpretation of the data but could be criticized because of concern over
whether the patients receiving placebo received adequate pain relief.
Contribution to the evidence: This study provides some data on the
efficacy of diclofenac and rofecoxib, as compared to placebo in
treatment of this condition. Given that rofecoxib is now withdrawn, the
efficacy of this drug is no longer relevant. However, the information from
this trial should help in designing future studies of NSAIDs in shoulder
pain, for example to define appropriate trial outcomes, sample size, and
other aspects of study design.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.Study Design
The study was a double-blind, 7-d randomized controlled trial
comparing placebo, rofecoxib 50 mg, and diclofenac 150 mg
using a double-dummy technique. The design of the study was
approved by the ethics committee of Cochin Hospital (Paris,
France). All patients gave their written informed consent
before entering the trial. The study was conducted in 47
centers from 15 April 2003 to 16 March 16 2004.
Interventions
Study drugs. After conﬁrmation of patient eligibility and
after written informed consent was obtained, patients were
randomly assigned to receive placebo, diclofenac 50 mg three
times daily, or rofecoxib 50 mg once daily. All the patients
took four capsules per day (two at breakfast, one at lunch, and
one at dinner) during the seven days of the trial, regardless of
the level of symptoms and the randomization group. Capsules
and packages were identical in appearance.
Compliance was evaluated by pill count at the ﬁnal visit.
Rescue therapies. Acetaminophen (500 mg tablets, max-
imum eight tablets/day) was used as analgesic treatment
during the study when needed. Since acetaminophen was
supplied as part of the study, a pill count of acetaminophen
was performed at ﬁnal visit.
In cases of persistent intolerable pain, a local injection of
steroidswasperformed.Thisinjectionwasdeﬁnedastreatment
failure,resultinginthewithdrawalofthepatientfromthetrial.
Objectives
The objective of this trial was to demonstrate the superiority
of NSAIDs over placebo in acute shoulder pain over a 7-d
treatment period.
Outcomes
Primary outcome measure. Changes in pain were consid-
ered as the primary outcome measure. The original trial
protocol was referring to a ‘‘clinically relevant’’ deﬁnition of
the primary outcome (e.g., a success deﬁned by a sustained
improvement of at least 50% and an absolute level of pain of
30 or less [0–100 normalized scale]). While the recruitment of
patients was still ongoing and based on discussion concerning
the potential loss of statistical power by using a dichotomous
variable instead of a continuous variable, an amendment was
proposed and accepted by the ethical committee to redeﬁne
the primary variable as the mean changes in pain during the
study. Since both techniques resulted in similar ﬁndings, we
are presenting here the results according to the original trial
protocol. For this purpose, a diary was provided to the
patient in order to collect twice a day (in the morning and in
the evening) his/her pain intensity over the 12 previous hours
(‘‘nocturnal’’ pain collected in the morning and ‘‘diurnal’’
pain collected in the evening) using a 0–10 NRS.
Secondary outcome measures. Functional impairment and
patient’s global assessment were considered as secondary
symptomatic outcome measures. Clinical assessment was
performed at baseline and after 7 d by the same investigator,
and functional impairment and patient’s global assessment
were collected. Functional impairment was evaluated using
the function subscale of Neer’s index [21]. This scale consists
of ten questions related to daily activities (1, use back pocket;
2, perineal care; 3, wash opposite axilla; 4, eat with utensil; 5,
comb hair; 6, use hand with arm at shoulder level; 7, carry 10–
15 pounds with arm at side; 8, dress; 9, sleep on side; 10, do
usual work). For each question, a score of 0 was assigned if the
activity could be performed without any difﬁculty, 1 with
some difﬁculty, 2 with marked difﬁculty, 3 with great
difﬁculty (requiring assistance), and 4 if impossible. There-
fore, this scale ranges from 0 to 40.
Patients’ global assessments were evaluated using three
different techniques. In one, at the baseline and the ﬁnal
visits, patient’s global assessment of disease activity was
collected by the following question ‘‘considering all the ways
your shoulder disease affects you, mark an (X) in the
appropriate box for how well you are doing’’ and the
following potential answers 0, very well; 1, well; 2, fair; 3,
poor; and 4, very poor. For the analysis, this variable was
considered as a continuous one and normalized from 0¼best
condition to 100 ¼ worst condition.
In a second technique, at the ﬁnal visit, patient’s global
assessment on her/his relative condition was collected by the
following question: ‘‘compared to when you started the study,
how have you been during the last 48 hours?’’ and the
following potential 15 answers from 7, very great deal worse
to þ7, very great deal better. For the analysis, we considered
this variable as a dichotomous one (e.g., improvement yes/no
in which an improvement was considered for the patients
answering at least ‘‘good deal better’’).
In a third technique, at the ﬁnal visit, acceptable symptom
state was assessed by the following question: ‘‘considering
your current level of pain and functional impairment, if you
were to remain for the next following months as you were
d u r i n gt h el a s t4 8h o u r sw o u l dt h i sb ea c c e p t a b l eo r
unacceptable to you?’’ and the potential following answers
0, acceptable; 1, not acceptable.
Moreover, the requirement for rescue therapies (e.g.,
acetaminophen intake and/or local injection of steroids) was
also considered as a secondary outcome measure of efﬁcacy.
At baseline and ﬁnal visit, blood pressure and body weight
were systematically collected and at ﬁnal visit, the inves-
tigators checked for tolerability.
Sample Size
The sample size needed in order to demonstrate a statistically
signiﬁcant difference between NSAID and placebo using the
pain intensity (mean of nocturnal and diurnal pain) was
calculated. A success was a priori deﬁned by a sustained
improvement of at least 50% and an absolute level of pain 30
or less (on a 0–100 normalized scale). The analysis was
conducted using the Kaplan-Meier technique in which the
event was deﬁned by the time the patient fulﬁlled the above
deﬁnition of improvement in pain with such an improvement
sustained until the end of the study. Based on information on
changes in pain in previously reported trials [22], the Kaplan-
Meier estimates of the percentage of patients achieving such
an improvement was expected to be around 40% in the active
group. Since, to our knowledge, no information was available
in the literature concerning the placebo group, we a priori
and arbitrarily expected a 20% success rate in the placebo
group. Thus a sample size of 82 patients per treatment group
would allow demonstration of this difference with an alpha
level of 0.05 and power of 0.80 two-tailed).
Randomization: Sequence Generation
A computer-generated randomization sequence assigned
participants in a 1:1:1 ratio to receive rofecoxib, diclofenac,
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recruited in the trial, a coded package for the drugs was used.
Randomization: Allocation Concealment
The randomization code was available only to the statistician
who did not participate in any way for patient recruitment.
The code was revealed to the researchers once recruitment,
data collection, and statistical analysis were complete. Because
of the double-dummy technique used with matching placebo,
allocation was concealed from both investigators and patients.
Randomization: Implementation
After checking that screened patients fulﬁlled the inclusion/
exclusion criteria of the study and after written informed
consent was obtained, the investigator assigned the patient on
an individual basis to an allocated number. The patient
remained on the same allocation throughout the study. The
investigatorsresponsibleforseeingthepatientsallocatedthem
to the next available number into the trial (in the rheumatol-
ogist/generalpractitioner’sofﬁce),andprovidedthetreatment
corresponding to the allocated number of the patients.
Blinding
This was a double-blind trial. Both the patients and the
physicians providing care were blinded of the study drug
allocation. For this purpose, a coded package for the drugs was
used. The active drugs and their corresponding placebos were
identical in appearance, color, and taste. The blinding process
remained complete until the database (e.g., all the information
concerning the patients and the course of the disease during
the seven days of the study) was completed and was locked.
Statistical Methods
The efﬁcacy analysis was conducted on the modiﬁed
intention to treat population, deﬁned as all patients
randomized in the study and receiving at least one dose of
study drug with the last observation carried forward
technique. For patients who withdrew without assessment,
the baseline value was reported as the ﬁnal value. All patients
were analyzed in the group to which they were randomized.
The primary efﬁcacy variable (success of treatment was
deﬁned by a decrease in pain of at least 50% and an absolute
level  30) was evaluated using life table analysis (Kaplan-
Meier technique) in which the event was deﬁned by the time
to reach a sustained deﬁnition of success until the end of the
study. The results are expressed as Kaplan-Meier estimates of
the percentage of success per treatment group at day 7. The
primary analysis consisted in the comparison between
rofecoxib and placebo groups using the log-rank test. As a
secondary analysis, diclofenac was also compared to placebo
according to the same deﬁnition of success.
Exploratory analyses were also performed using the same
approach (life table analysis) but with different deﬁnitions of
event (success): time to reach an improvement of 50%; time
to reach an improvement of 50% and such an improvement is
maintained during the remaining days of the study; time to
reach an absolute level of pain   30; and time to reach an
absolute level of pain   30 and such a good condition is
maintained during the remaining days of the study.
The continuous secondary variables are also expressed in
normalized units using a 0–100 scale in which 0 ¼ best
condition and 100 ¼ worst condition. Absolute changes
between day 0 and day 7 of ‘‘nocturnal pain,’’ diurnal pain,’’
‘‘number of pills of acetaminophen,’’ ‘‘functional impair-
ment,’’ and ‘‘patient’s global assessment’’ were compared with
a nonparametric Mann-Whitney test. The dichotomous
secondary variables (‘‘patients considering their condition
as improved,’’ ‘‘patients considering themselves as feeling
well,’’ ‘‘patients considering their current status as accept-
able,’’ and ‘‘patients requiring a local injection of steroids’’)
were compared using the Chi-square test.
In order to estimate the clinical relevance of the observed
treatment effect on the requirement for local steroid
injection, the number needed to treat and its 95% conﬁdence
interval were calculated.
Statistical analysis was performed using SAS version 8.2
(SAS Institute, http://www.sas.com).
RESULTS
Participant Flow
Of the 274 screened patients, 273 were randomized but only
271 had at least one drug intake (see Figure 1). Most of the
patients completed the 7 d of the trial (93.6%, 93.3%, and
94.3% completer rate in the placebo, diclofenac, and
rofecoxib groups, respectively). The main reason for dis-
continuation was either inefﬁcacy (3, 2, and 1 patients in the
placebo, diclofenac, and rofecoxib groups, respectively) or
side effects (4, 2, and 2 patients in the placebo, diclofenac,
and rofecoxib group, respectively).
Compliance was considered as good since the mean capsule
intake was 94.5%, 93.0%, and 93.8% of the theoretical total
in the placebo, diclofenac, and rofecoxib groups, respectively.
Recruitment Period
The recruitment of the patients started in April 2003 and
ended in March 2004.
Baseline Data
Table 1 summarizes patient characteristics at the start of the
trial by treatment group. There was no obvious difference in
demographic data or clinical variables among the three
treatment groups at baseline.
Number Analyzed
All the randomized patients with at least one drug intake
were analyzed (i.e., 94, 89, and 88 in the placebo, diclofenac,
and rofecoxib groups, respectively)
Outcomes and Estimation
The percentage of patients achieving the deﬁnition of success
over time during the trial by treatment group is summarized
in Figure 2. The Kaplan-Meier estimates of the percentage of
success at day 7 was 38%, 54%, 56% in placebo, diclofenac,
and rofecoxib groups, respectively, with a highly signiﬁcant
difference between the placebo and rofecoxib groups (p ¼
0.025). Table 2 shows the percentage of patients considered as
a success by treatment group at the end of the trial
considering not only the primary efﬁcacy criterion (sustained
improvement of at least 50% and absolute level of pain  30
on a 0–100 scale) but also the secondary efﬁcacy variables
concerning the deﬁnition of success. Similar results were
obtained when success was deﬁned as pain lessening using the
same analysis (life table analysis) but with different thresholds
to deﬁne the event (unpublished data).
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treatment groups are summarized in Table 3. Except for
acetaminophen pill intake, all the variables strongly favored the
rofecoxiband/orthediclofenacgroupwhencomparedtoplacebo.
At the end of the trial, the percentage of patients
considering their condition as substantially improved or as
acceptable was more important in the two active groups than
in the placebo group (see Table 2). Moreover, during the
seven days of the study (and most often at the ﬁnal visit), a
local injection of steroids was required by 35% of the patients
receiving placebo, a higher percentage than in the diclofenac
and rofecoxib groups (19% and 22%, respectively). Based on
these data, it was estimated that the number of patients
needed to treat in order to avoid the requirement of one
Figure 1. Patients and Study Course
doi:10.1371/journal.pctr.0020009.g001
.......................................................................................................................................................................................
Table 1. BaselineCharacteristicsofthe271RandomizedandTreatedPatientswithPainfulRotatorCuffSyndromebyTreatmentGroup
Characteristics Treatment Group
Placebo Diclofenac 50 mg 3 3 Rofecoxib 50 mg 3 1
Patients (n) 94 89 88
Female (% patients) 64 62 61
Age (y) mean 6 SD 47 6 10 48 6 12 48 6 10
Shoulder symptoms in the dominant-hand side (% patients) 63% 70% 55%
Shoulder symptom duration (y) mean 6 SD 2.1 6 2.1 2.7 6 3.5 2.2 6 2.7
Acute episode duration (d) mean 6 SD 5.0 6 1.9 5.3 6 3.4 5.4 6 1.8
Symptom progression: Current episode is the first one (% patients) 33 27 31
Symptom progression: Chronic pain before this first acute episode (% patients) 12 8 15
Symptom progression: History of similar acute episodes without interepisode
chronic pain (% patients)
38 39 43
Symptom progression: History of similar acute episodes with interepisode chronic
pain (% patients)
22 27 21
SD, standard deviation
doi:10.1371/journal.pctr.0020009.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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(95% conﬁdence interval 5–15).
Adverse Events
Thirty-nine patients (13 patients in each group) experienced
at least one adverse event (53 in total) during the study.
Gastrointestinal disorders (mainly upper abdominal pain and
nausea) occurred in 12 (12.8%), 11 (12.4%), and 9 (10.2%) in
the placebo, diclofenac, and rofecoxib groups, respectively.
In the rofecoxib group, one patient had to be hospitalized
2 d after the end of the study because of an ulcer
perforation; outcome was favorable after surgery. There
was no death and no cardiovascular event. During the study,
eight patients had to discontinue the study drug mainly
because of gastro-intestinal discomforts. The most frequent
adverse events observed during the trial are summarized in
Table 4.
Figure 2. Percentage of Acute Painful Shoulder Patients Fulfilling the Definition of Success over Time by Treatment Group
(A) Success was defined by a decrease in pain of at least 50% and an absolute level   30 (on a 0–100 scale). Moreover, such definition required that such
condition should be sustained until the end of the 7 days of the study.
(B) Number of patients at risk per treatment group at the beginning of each interval.
doi:10.1371/journal.pctr.0020009.g002
.......................................................................................................................................................................................
Table 2. Percentage of Patients Considered as Treatment Success Based on Different Definitions by Treatment Group at the End of
the Study
End Point Treatment Group Comparisons
Placebo
(n ¼ 94)
Diclofenac
50 mg 3 3
(n ¼ 89)
Rofecoxib
50 mg 3 1
(n ¼ 88)
Rofecoxib/
Placebo
p-Value
a
Diclofenac/
Placebo
p-Value
b
Primary variable
c 38% 54% 56% 0.0070 0.0239
Patients considering their condition as improved
d 69% 76% 86% 0.0129 0.5058
Patients considering feeling well
e 21% 46% 43% 0.0064 0.0074
Patients considering their current status as acceptable
f 32% 53% 57% 0.0007 0.0042
Patients requiring a local injection of steroids 35% 19% 22% 0.0437 0.0152
aStatistical significance between the rofecoxib and placebo groups determined by either the log-rank test (primary variable) or the Chi-square test (all other variables).
bStatistical significance between the diclofenac and placebo groups determined by either the log-rank test (primary variable) or the Chi-square test (all other variables).
cPrimary variable: Time to reach a sustained improvement of at least 50% and an absolute level  30 in pain intensity (mean of the nocturnal and diurnal pain). Data presented are the
Kaplan-Meier estimates of the percentage of patients at day 7.
dImproved condition: Patient considers her/his condition as at least ‘‘good deal better’’ on a 15-point Likert scale (from  7 ¼ a great deal worse to þ7 ¼ a great deal better) when
compared to prior therapy.
eFeeling well: Patient considers her/his current health status as ‘‘well’’ or ‘‘very well’’ on a 5-point Likert scale.
fAcceptable condition: Patient considers her/his current condition as acceptable taking were she/he to remain for the next several months as she/he was during the last 48 h in terms of
both pain and functional impairment.
doi:10.1371/journal.pctr.0020009.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Interpretation
This study conﬁrms the short term symptomatic efﬁcacy of
NSAIDs (either conventional such as diclofenac or selective
Cox-2 inhibitors such as rofecoxib) in acute shoulder pain.
The observed treatment effect in the a priori selected
outcome variable (i.e., 54% and 56% versus 38% in the
diclofenac and rofecoxib versus placebo groups) reached
statistical signiﬁcance and was also close to the a priori
expected treatment effect (i.e., a difference of 20% between
active and placebo). The interpretation of results is made
difﬁcult by the fact that there is no clear consensus on the
primary outcome variable which should be chosen in this type
of study. However, the positive and statistically signiﬁcant
results in favor of NSAIDs in the secondary outcome
variables, especially the requirement for steroid injections,
support the primary analysis. Finally, the interpretation of
the results should also take into account issues related to both
the eligibility criteria, the outcome measures, and the choice
of the study drugs (in particular the placebo).
Eligibility Criteria
There is no current, formal recommendation for conducting
clinical trials in shoulder pain syndrome, at least to our
knowledge. The design of the currently reported trial was
based on knowledge of the disease and of the commonly used
outcome variables in musculoskeletal disorders. Concerning
the disease, reviews on diagnostic criteria for shoulder pain
conclude that current diagnostic tools are not evidence based
[23]. The main objective when establishing exclusion criteria
of the present study were to try to avoid the inclusion of
patients suffering from glenohumeral osteoarthritis and/or
adhesive capsulitis. For this purpose, we excluded patients
over 60 years old and patients with an abnormal glenohum-
eral external rotation (the most commonly limited range of
motion in osteoarthritis and/or adhesive capsulitis [4]). The
.......................................................................................................................................................................................
Table 3. Baseline Values and Mean Changes in Clinical Variable and Use of Acetaminophen after Seven Days of the Study, by
Treatment Group
Variable
a Baseline Changes during the Study Comparisons
Placebo
(n ¼ 94)
Diclofenac
50 mg 3 3
(n ¼ 89)
Rofecoxib
50 mg 3 1
(n ¼ 88)
Placebo
(n ¼ 94)
Diclofenac
50 mg 3 3
(n ¼ 89)
Rofecoxib
50 mg 3 1
(n ¼ 88)
Rofecoxib/
Placebo
p-Value
b
Diclofenac/
Placebo
p-Value
c
Nocturnal pain
(NRS 0–100)
a
63 6 22; 70
[50 to 80]
63 6 20; 70
[50 to 80]
66 6 21; 70
[50 to 80]
 27 6 28;  20
[ 50 to  10]
 35 6 28;  40
[ 50 to  20]
 35 6 27;  40
[ 50 to  15]
0.0496 0.0351
Diurnal pain
(NRS 0–100)
a
68 6 14; 70
[60 to 80]
68 6 16; 70
[60 to 80]
68 6 14; 70
[60 to 80]
 27 6 25;  20
[ 50 to  10]
 36 6 25;  40
[ 50 to  20]
 38 6 26;  40
[ 50 to  20]
0.0021 0.0150
Functional
impairment
a
47 6 16; 45
[35 to 58]
46 6 17; 48
[35 to 58]
49 6 16; 50
[37 to 59]
 18 6 21;  18
[ 28 to  3]
 22 6 24;  18
[ 38 to  8]
 27 6 20;  25
[ 40 to  10]
0.0049 0.2727
Patient’s global
assessment
a
68 6 16; 75
[50 to 75]
69 6 18; 75
[50 to 75]
70 6 14; 75
[63 to 75]
 15 6 27;  15
[ 25 to 0]
 28 6 32;  25
[ 50 to 0]
 30 6 2.7;  25
[ 50 to  13]
0.0002 0.0059
Acetaminophen
(number of pills)
—— —
 0.02 6 2.05; 0
[ 1; 1]
 0.07 6 1.83; 0
[ 1t o1 ]
0.09 6 2.56; 0
[ 1t o1 ]
0.9910 0.9246
Values are presented as mean 6 SD (first raw); median [95% confidence intervals] (second raw).
aThe values of all the scales were normalized to 0–100 where 0 ¼ the best condition and 100 ¼ the worst condition.
bStatistical significance determined by nonparametric Mann-Whitney test comparing rofecoxib and placebo.
cStatistical significance determined by nonparametric Mann-Witney test comparing diclofenac and placebo.
doi:10.1371/journal.pctr.0020009.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 4. Adverse Events by Treatment Group Observed during the Seven Days of the Trial
Adverse Event Treatment Groups
Placebo (n ¼ 94) Diclofenac (n ¼ 89) Rofecoxib (n ¼ 88)
Ear and labyrinth disorders 0 (0.0%) 2 (2.2%) 0 (0.0%)
Gastrointestinal disorders 15 (16.0%) 11 (12.4%) 11 (12.5%)
Abdominal pain 6 (6.4%) 6 (6.7%) 3 (3.4%)
Diarrhea 2 (2.1%) 2 (2.2%) 0 (0.0%)
Dyspepsia, flatulence, and reflux gastritis 2 (2.1%) 2 (2.2%) 0 (0.0%)
Gastrointestinal ulcer perforation 0 (0.0%) 0 (0.0%) 1 (1.1%)
Nausea, vomiting 5 (5.3%) 1 (1.1%) 7 (7.9%)
General disorders and administration site conditions 1 (1.1%) 0 (0.0%) 2 (2.3%)
Infections and infestations 0 (0.0%) 0 (0.0%) 1 (1.1%)
Musculoskeletal and connective tissue disorders 1 (1.1%) 0 (0.0%) 0 (0.0%)
Nervous system disorders 1 (1.1%) 0 (0.0%) 2 (2.3%)
Respiratory, thoracic, and mediastinal disorders 1 (1.1%) 0 (0.0%) 1 (1.1%)
Skin and subcutaneous tissue disorders 1 (1.1%) 0 (0.0%) 1 (1.1%)
Vascular disorders 0 (0.0%) 0 (0.0%) 1 (1.1%)
Others 0 (0.0%) 1 (1.1%) 0 (0.0%)
Data given as number (percentage of n patients).
doi:10.1371/journal.pctr.0020009.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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second objective was to try to avoid patients with massive
rotator cuff tears and/or ruptures. Based on the data found in
the literature, we considered that the Job’s test was the most
discriminant for this purpose [19,20].
Outcome Measures
While designing the trial, concerning the choice of the
outcome measures used in this trial, we considered three key
aspects: Which domain? Which instrument? Which analysis?
The ultimate goal of any therapeutic intervention for
shoulder pain is the restoration of pain-free function [3].
Based on this objective, we focused our research on the three
domains commonly selected in musculoskeletal disorders, i.e.,
pain, functional impairment, and the patient’s global assess-
ment. For each of these domains, we selected speciﬁc tools,
items, and/or instruments we considered to be the most
adequate. For the domain ‘‘pain,’’ it seemed important to
collect its degree of severity both during the night and during
daily activities. There is no consensus related to the optimal
questionnaire evaluating shoulder disability [24]. The scoring
system proposed by Neer is a composite index combining the
information from four different domains: pain, range of
motion, functional impairment, and patient’s global [21]. This
scoring system is frequently used for the evaluation of
orthopedic procedures. For our trial we considered that the
function subscale was appropriate, since it is relevant and
simple to use. Finally patient’s global assessment is an
important domain to consider, as was recently re-emphasized
during a meeting about rheumatology and methodology for
trials [25]. In our study, the patient’s global assessment was
evaluated in different ways. First, we used a ‘‘conventional’’
approach by evaluating the changes during the study of the
current status of the patient using a 5-point Likert scale
[26,27]. Second, we evaluated the concept of minimum
clinically important improvement [28] by questioning the
patient at the end of the study about the clinical relevance of
the changes she/he noted during the study [29]. Thirdly, we
also evaluated the concept of patient-acceptable symptom
state by questioning the patient at the end of the trial about
her/his acceptability of the current status [30].
The report results also anticipated considering that
presentation at an individual level is probably more relevant
than presentation at a group level [28–30]. Therefore, instead
of choosing mean changes as the primary variable, we
selected the presentation at an individual level. There are
several possibilities of presentation of results at an individual
level: the ﬁrst step is to choose between the concept of
responder (to be in a better condition) and the concept of
status (to be in a good condition). The concept of status
seemed to be more relevant [31] and more appropriate in
acute painful conditions in which the main objective is to
attain a pain-free condition [3]. Moreover, the onset of action
is also important to consider. This concept (to feel good as
soon as possible and to maintain such a good condition
during the study) was the rationale of the choice of the
primary variable used in this study.
The choice of the threshold of 30/100 in degree of severity
of pain below which the patient considers her/his status as
acceptable was arbitrarily chosen but was close to other
patient-acceptable symptom state thresholds recently re-
ported [30,32].
Study Drugs (Placebo Arm)
Because of the huge variability of symptoms in most painful
musculoskeletal disorders, a placebo arm is usually encour-
aged in order to facilitate the interpretation of the results.
Such a placebo arm seems acceptable from an ethical point of
view if the patient has the opportunity to obtain an optimal
rescue therapy. This was the case in this trial during which a
persistent painful condition was treated by use of acetami-
nophen and if necessary by local injections of steroids.
Despite the fact that we did not perform formal compa-
rative statistical testing, data obtained in this trial are in favor
of a similar treatment effect for rofecoxib and diclofenac.
However, we have to re-emphasize the fact that because of
cardiovascular safety concerns, rofecoxib has been withdrawn
from the market. This study, conducted during a very short
period of time without further follow-up of patients, cannot
contribute toward the assessment of safety.
Generalizability
Based on this study, it is hard to generalize the obtained
results with regard to both the study drugs and clinical
condition being evaluated. In particular, such a study does
not allow a conclusion that any NSAID at any dose might be
beneﬁcial in such conditions. Also, such a study does not
allow conclusions to be made that positive clinical beneﬁt
may be identical in another musculoskeletal condition (such
as epicondylitis or achilleus tendinitis).
Overall Evidence
A Cochrane review on therapeutic interventions for acute
shoulder pain currently does not include an estimate of the
treatment effect of NSAIDs for this particular condition [33].
A recent systematic literature review found inconclusive
evidence on the effects of oral NSAIDs in people with
shoulder pain [34]. Positive results with other NSAIDs/coxibs
have been reported, but only in open and/or comparative
trials [5,8,21,35]. A single trial, using a prospective placebo
design (similar to the currently reported one), compared the
two-week symptomatic efﬁcacy of celecoxib 200 mg twice
daily and naproxen 500 mg twice daily versus placebo, and
showed similar results with a superiority of both celecoxib
and naproxen when compared to placebo [13].
Finally, other studies are needed in order to evaluate the
best dose regimen and the best therapeutical strategy, in
particular whether it might be more clinically relevant to
perform as the ﬁrst step an NSAID/coxib intake and there-
after (in case of failure) a local injection of steroids (as has
been evaluated in this trial) versus a local injection of steroids
without oral drugs as the ﬁrst step versus the combination of
oral drug and local injection of steroids.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0020009.sd001 (50 KB DOC).
Trial Protocol (Original)
Found at doi:10.1371/journal.pctr.0020009.sd002 (413 KB DOC).
Trial Protocol (Amendment)
Found at doi:10.1371/journal.pctr.0020009.sd003 (384 KB DOC).
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